Name: KARINE GADIOLI DE OLIVEIRA
Publication date: 25/06/2018
Advisor:
Name |
Role |
|---|---|
| NAZARE SOUZA BISSOLI | Co-advisor * |
| SONIA ALVES GOUVEA | Advisor * |
Examining board:
| Name |
Role |
|---|---|
| CARMEM LUIZA SARTORIO | Internal Examiner * |
| ESTER MIYUKI NAKAMURA PALACIOS | Internal Examiner * |
| NAZARE SOUZA BISSOLI | Co advisor * |
| SONIA ALVES GOUVEA | Advisor * |
Summary: Currently, cancer is the second largest cause of death in Brazil, surpassed only by cardiovascular diseases. Oncologic therapy has evolved and improved the prognosis in cancer patients. However, despite the unquestionable clinical benefit of this type of therapy, many of these drugs can cause undesirable side effects in the cardiovascular system. Head and neck cancer is the sixth most common cancer in the world and the prognosis for these types of patients is poor and has not improved in the last decades. Head and neck cancer patients have a high risk of non-cancer related mortality and one of the most frequent causes is cardiovascular disease. Therefore, the aim of this study was to evaluate the predictive value of C Reactive Protein (CRP), N-terminal proB-type natriuretic peptide (NT-proBNP), cardiac troponin T (cTnT), and cytokines (IL-17A, INF-γ, TNF-α, IL-10, IL-6, IL-4) in cardiovascular risk associated with oncologic therapy in head and neck squamous cell carcinoma. Thus, 118 patients with confirmed diagnosis of head and neck squamous cell carcinoma have been included in this study, and clinical-epidemiological data have been obtained with blood collection before and after cancer therapy. This current study has shown that high levels of CRP and NT-proBNP are associated with poor 3-year overall survival and poor prognosis, unrelated to gender, age, smoking or alcohol consumption, staging, primary tumor location, body mass index, systolic blood pressure, and treatment (except radiotherapy). Although cTnT did not influence the survival of these patients, it has been positively correlated to surgical treatment and radiochemotherapy. In addition, an imbalance in pro- and anti-inflammatory cytokine profile has been observed after treatment, with an increase in il-6 and reduction of IL-10, IL-4 and TNF-α. Therefore, strategies that evaluate and follow up patients with head and neck cancer during treatment are extremely important to improve the response to treatment or to implement new therapies to increase survival and provide quality of life for head and neck cancer patients.
